Compare Gitlab Inc (GTLB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Gitlab Inc trades at $55.07 (market cap $8.92B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Gitlab Inc and State Street SPDR S&P Biotech ETF are close in size by market cap, and Gitlab Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GTLB | XBI | |
|---|---|---|
Market Cap | $8.92B | $10.11B |
Volume | 4,716,893 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $53.56 | $169.55 |
52-Week Low | $19.42 | $104.99 |
Typical Hold Time | 62 Days | 38 Days |
Enterprise Value | $7.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $55.09, up 5.96% today and near its 52-week high, with strong technical momentum. The company shows impressive revenue growth, reaching $759M in 2025, though it remains unprofitable with a net margin of -4.99%. Recent Q2 2026 earnings beat expectations with EPS of $0.24 versus $0.18 expected, driven by AI product traction and sales momentum. Analyst sentiment is mixed with a Hold consensus but positive news flow highlights AI-driven demand and raised guidance.
Outlook: GTLB benefits from AI integration in DevSecOps and strong execution, but high valuation (P/E 521) and persistent losses pose risks. Investment case hinges on sustained revenue growth and path to profitability. Key risks include competitive pressure and reliance on AI adoption trends.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
